Drug
Consolidative immunotherapy
Consolidative immunotherapy is a pharmaceutical drug with 3 clinical trials. Currently 3 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(100%)
Phase Distribution
Ph phase_3
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 33 (100.0%)
Trials by Status
recruiting3100%
Recent Activity
3 active trials
Showing 3 of 3
recruitingphase_3
Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI
NCT06545747
recruitingphase_3
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
NCT06734702
recruitingphase_3
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
NCT07052669
Clinical Trials (3)
Showing 3 of 3 trials
NCT06545747Phase 3
Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI
NCT06734702Phase 3
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
NCT07052669Phase 3
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3